Adial Pharmaceuticals, Inc (ADIL) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ADIL SEC filings page.
This page shows Adial Pharmaceuticals, Inc (ADIL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
With no reported revenue, the company funds recurring operating losses mainly through external financing, not internally generated cash.
In FY2025, it used$6.5M in operating cash against an operating loss of$7.8M ; the narrower cash use suggests non-cash or working-capital items softened the cash impact. Financing provided$8.5M , exceeding that operating use, so liquidity depends on capital raised outside operations rather than business-generated cash.
The balance sheet became more leveraged than in FY2023: liabilities increased from
Reported FY2025 SG&A of
Financial Health Signals
Adial Pharmaceuticals, Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Adial Pharmaceuticals, Inc reported -$52.0M in net income in Q2 2026. This represents a decrease of 2555.2% from the same quarter a year earlier. Against the prior quarter it is down 2469.9%.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Adial Pharmaceuticals, Inc held $28.7M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
Adial Pharmaceuticals, Inc invested $440K in research and development in Q2 2026. This represents a decrease of 39.9% from the same quarter a year earlier. Against the prior quarter it is up 1.7%.
Not reported for Q2 2026.
Not reported for Q2 2026.
ADIL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $440K-39.9% | $433K-42.1% | N/A | $521K-49.5% | $732K-27.7% | $747K+64.4% | N/A | $1.0M+398.1% |
| SG&A Expenses | $5.4M+369.6% | $1.6M+3.2% | N/A | $1.2M+5.4% | $1.1M-9.8% | $1.5M+9.3% | N/A | $1.2M+2.5% |
| Operating Income | -$52.0M-2664.3% | -$2.0M+11.7% | N/A | -$1.8M+20.2% | -$1.9M+17.7% | -$2.3M-22.9% | N/A | -$2.2M-62.9% |
| Net Income | -$52.0M-2555.2% | -$2.0M+9.2% | N/A | -$1.8M+18.2% | -$2.0M+20.4% | -$2.2M+65.6% | N/A | -$2.2M-58.3% |
| EPS (Basic) | -$11.25-144.0% | -$1.48+82.6% | -$11.48-7553.3% | -$0.08+78.9% | -$4.61-681.4% | -$8.52-289.0% | -$0.15+79.7% | -$0.38+67.8% |
| EPS (Diluted) | -$11.25 | -$1.48 | -$11.48 | -$0.08 | -$4.61 | -$8.52 | -$0.15+79.7% | -$0.38 |
| Diluted Shares (Avg) | 5M | 1M | N/A | 22M | 424,908 | 261,590 | N/A | 6M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Interest Expense, Income Tax.
ADIL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $29.1M+327.7% | $5.2M+51.5% | $6.7M+32.3% | $5.7M-15.7% | $6.8M+37.4% | $3.5M | $5.0M+6.5% | $6.7M+134.1% |
| Current Assets | $28.8M+374.5% | $4.8M+82.7% | $6.2M+52.3% | $5.0M-10.8% | $6.1M+59.0% | $2.6M | $4.1M+26.9% | $5.6M+394.8% |
| Cash & Equivalents | $28.7M+385.4% | $4.6M+93.8% | $5.9M+56.8% | $4.6M-11.5% | $5.9M+79.9% | $2.4M-52.9% | $3.8M+32.7% | $5.2M+1547.6% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $67.5M+5471.0% | $1.5M+14.0% | $1.4M+43.2% | $1.2M+39.3% | $1.2M+80.2% | $1.3M | $976K+49.4% | $829K+57.0% |
| Current Liabilities | $5.1M+322.9% | $1.5M+14.0% | $1.4M+43.2% | $1.2M+39.3% | $1.2M+80.2% | $1.3M | $976K+49.4% | $829K+57.0% |
| Non-Current Liabilities | $62.3M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Equity | -$38.4M-786.5% | $3.7M+74.8% | $5.3M+29.7% | $4.5M-23.4% | $5.6M+30.7% | $2.1M-65.3% | $4.1M-0.4% | $5.9M+151.5% |
| Retained Earnings | -$144.0M-67.1% | -$92.0M-9.2% | -$90.0M-9.7% | -$88.0M-10.1% | -$86.2M-10.9% | -$84.2M | -$82.0M-19.2% | -$79.9M-19.5% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
ADIL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$6.4M-263.7% | -$1.6M-1.7% | -$1.3M+8.9% | -$1.8M-8.2% | -$1.7M+18.6% | -$1.6M+2.5% | -$1.5M-18.9% | -$1.7M-21.8% |
| Stock-Based Compensation | $137K+10.5% | $148K-37.5% | N/A | $147K-21.7% | $124K-38.7% | $237K+4.8% | N/A | $188K-29.9% |
| Investing Cash Flow | N/A | N/A | $0 | $0 | $0 | $150K | N/A | N/A |
| Financing Cash Flow | $25.2M+375.8% | $315K+522.5% | $2.6M | $525K-85.5% | $5.3M+1188.9% | $51K-98.7% | $0-100.0% | $3.6M+2503.6% |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
ADIL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | N/A | -54.4%+50.4pp | N/A | -39.8%-2.6pp | -35.0%+22.4pp | -104.8%+1.0pp | N/A | -37.3%+22.0pp |
| Return on Assets | -178.7%-149.9pp | -38.7%+25.9pp | N/A | -31.7%+1.0pp | -28.8%+20.9pp | -64.6% | N/A | -32.6%+15.6pp |
| Current Ratio | 5.63+0.6x | 3.18+1.2x | 4.42+0.3x | 4.34-2.4x | 5.02-0.7x | 1.99 | 4.16-0.7x | 6.78+4.6x |
| Debt-to-Equity | N/A | 0.41-0.2x | 0.260.0x | 0.26+0.1x | 0.22+0.1x | 0.62 | 0.24+0.1x | 0.14-0.1x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Adial Pharmaceuticals, Inc ADIL | FY2025 | N/A | N/A | N/A | $9.7M | — |
| Alzamend Neuro, Inc. ALZN | FY2026 | N/A | -$8.8M | N/A | $6.5M | — |
| VYNE Therapeutics Inc. VYNE | FY2025 | $570K | -$26.5M | N/A | $19.1M | — |
| BRAINSTORM CELL THERAPUTC BCLI | FY2025 | N/A | N/A | N/A | $12.0M | — |
| TNF Pharmaceuticals, Inc. TNFA | FY2025 | N/A | -$11.6M | N/A | $9.6M | — |
| Creative Medical Technology Holdings, Inc. CELZ | FY2025 | $6K | -$6.0M | N/A | $6.2M | — |
Where Adial Pharmaceuticals, Inc Ranks
Frequently Asked Questions
What is Adial Pharmaceuticals, Inc's operating cash flow?
Adial Pharmaceuticals, Inc (ADIL) recorded an outflow of $6.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Adial Pharmaceuticals, Inc's total assets?
Adial Pharmaceuticals, Inc (ADIL) had $6.7M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Adial Pharmaceuticals, Inc spend on research and development?
Adial Pharmaceuticals, Inc (ADIL) invested $2.6M in research and development during fiscal year 2025.
What is Adial Pharmaceuticals, Inc's current ratio?
Adial Pharmaceuticals, Inc (ADIL) had a current ratio of 4.42 as of fiscal year 2025, which is generally considered healthy.
What is Adial Pharmaceuticals, Inc's debt-to-equity ratio?
Adial Pharmaceuticals, Inc (ADIL) had a debt-to-equity ratio of 0.26 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Adial Pharmaceuticals, Inc's P/E ratio?
Adial Pharmaceuticals, Inc (ADIL) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $9.7M as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Adial Pharmaceuticals, Inc's price-to-sales ratio?
Adial Pharmaceuticals, Inc (ADIL) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $9.7M as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Adial Pharmaceuticals, Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Adial Pharmaceuticals, Inc (ADIL) held $5.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $6.5M over that year. Dividing the one by the other, the reported balance equals about 11 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.